Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cécile Chougnet

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Presse Medicale (Paris, France : 1983)|November 15, 2011
[Refractory thyroid cancers]Martin Schlumberger, Cécile Chougnet, Eric Baudin, et al.
Plos One|January 25, 2012
Angiopoietin 2 alters pancreatic vascularization in diabetic conditionsSophie Calderari, Cécile Chougnet, Maud Clemessy, et al.
Clinics (Sao Paulo, Brazil)|May 16, 2012
Kinase inhibitors for advanced medullary thyroid carcinomaMartin Schlumberger, Marie-Hélène Massicotte, Camila L Nascimento, et al.
Bulletin Du Cancer|July 9, 2013
[Medullary thyroid carcinoma in children]Amandine Berdelou, Dana Hartl, Abir Al Ghuzlan, et al.
Therapeutic Drug Monitoring|February 24, 2018
Development and Validation of a Simultaneous Quantification Method of Ruxolitinib, Vismodegib, Olaparib, and Pazopanib in Human Plasma Using Liquid Chromatography Coupled With Tandem Mass SpectrometryClaire Pressiat, Huu-Hien Huynh, Alain Plé, et al.
Thyroid : Official Journal of the American Thyroid Association|August 3, 2012
Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levelsSophie Leboulleux, Intidhar El Bez, Isabelle Borget, et al.
International Journal of Cancer|April 23, 2014
SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paragangliomaJulien Hadoux, Judith Favier, Jean-Yves Scoazec, et al.
The Journal of Clinical Endocrinology and Metabolism|July 26, 2013
One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paragangliomaSégolène Hescot, Sophie Leboulleux, Laurence Amar, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Presse Medicale (Paris, France : 1983)|November 15, 2011
[Refractory thyroid cancers]Martin Schlumberger, Cécile Chougnet, Eric Baudin, et al.
Plos One|January 25, 2012
Angiopoietin 2 alters pancreatic vascularization in diabetic conditionsSophie Calderari, Cécile Chougnet, Maud Clemessy, et al.
Clinics (Sao Paulo, Brazil)|May 16, 2012
Kinase inhibitors for advanced medullary thyroid carcinomaMartin Schlumberger, Marie-Hélène Massicotte, Camila L Nascimento, et al.
Bulletin Du Cancer|July 9, 2013
[Medullary thyroid carcinoma in children]Amandine Berdelou, Dana Hartl, Abir Al Ghuzlan, et al.
Therapeutic Drug Monitoring|February 24, 2018
Development and Validation of a Simultaneous Quantification Method of Ruxolitinib, Vismodegib, Olaparib, and Pazopanib in Human Plasma Using Liquid Chromatography Coupled With Tandem Mass SpectrometryClaire Pressiat, Huu-Hien Huynh, Alain Plé, et al.
Thyroid : Official Journal of the American Thyroid Association|August 3, 2012
Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levelsSophie Leboulleux, Intidhar El Bez, Isabelle Borget, et al.
International Journal of Cancer|April 23, 2014
SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paragangliomaJulien Hadoux, Judith Favier, Jean-Yves Scoazec, et al.
The Journal of Clinical Endocrinology and Metabolism|July 26, 2013
One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paragangliomaSégolène Hescot, Sophie Leboulleux, Laurence Amar, et al.
Pageof 1